← Back to GLP-G3 product page
Biblioteca de investigación
Published research on this compound — for educational purposes only
How does GLP-G3 engage three receptor types simultaneously? (for educational purposes only)
GLP-G3 (LY3437943) is a single peptide engineered to activate GIP, GLP-1, and glucagon receptors through distinct structural domains within one alpha-helical chain. The peptide backbone incorporates sequence elements from all three native ligands, with the N-terminal region primarily driving glucagon and GLP-1 receptor activation and mid-chain residues contributing to GIP receptor engagement. A C-20 fatty diacid moiety enables albumin binding for extended half-life. In cell-based assays, GLP-G3 demonstrates agonist activity at all three receptors with engineered potency ratios. Research compound — not for human use.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
What does the glucagon receptor component contribute to GLP-G3’s pharmacology? (for educational purposes only)
The glucagon receptor (GCGR) agonist component distinguishes GLP-G3 from dual GIP/GLP-1 agonists. Glucagon receptor activation in preclinical models has been associated with increased hepatic lipid oxidation and elevated energy expenditure through thermogenic pathways. In cell-based assays, GLP-G3 activates GCGR-mediated cAMP signaling, engaging hepatic metabolic pathways distinct from those activated by GLP-1R or GIPR. The inclusion of GCGR agonism creates a pharmacological profile not achievable with mono- or dual-agonist compounds, engaging liver, pancreas, and adipose tissue receptor populations simultaneously. Research compound — not for human use.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
How does GLP-G3 compare structurally to dual agonists like GLP-2 T? (for educational purposes only)
While GLP-2 T engages two receptors (GIP and GLP-1), GLP-G3’s peptide sequence was engineered to additionally activate the glucagon receptor — requiring incorporation of glucagon-derived residues not present in dual agonist designs. Both compounds share lipidation strategies (C-20 fatty diacid for albumin binding) and DPP-4 resistance modifications, but GLP-G3’s sequence diverges substantially to accommodate three-receptor cross-reactivity within a single linear peptide. The structural challenge of maintaining potency at three distinct class B GPCRs simultaneously required extensive sequence optimization. Research compound — not for human use.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
What is GLP-G3’s receptor potency profile across GIP, GLP-1, and glucagon receptors? (for educational purposes only)
In vitro characterization demonstrates that GLP-G3 activates all three target receptors with distinct potency ratios. The compound shows highest relative potency at the GIP receptor, followed by GLP-1R, with moderate but pharmacologically relevant GCGR agonism. EC₅₀ values for cAMP accumulation at each receptor have been characterized in HEK293 cells expressing human receptors. The intentional potency imbalance — strongest at GIPR, intermediate at GLP-1R, and lowest at GCGR — was engineered to balance the overall receptor activation profile during preclinical characterization. Research compound — not for human use.
Citation: Coskun T, Urva S, Roell WC, et al. Cell Metab. 2022;34(9):1234-1247.e9. PubMed
To compare published studies with Panda batch documentation, review Reportes de laboratorio (COAs), Calidad y pruebas, la guía para evaluar materiales de investigación, o nuestras Preguntas frecuentes.
Disclaimer: All research citations are provided as references to published laboratory literature only. These materials may summarize in vitro and animal-model findings. Products are sold strictly for laboratory research use. No statements on this page are intended as dosing, administration, treatment, or other human-use guidance.
Reviewed by
Dr. James Porter, PhD
Biochemist with a focus on peptide synthesis and structure-activity relationships. Reviews research summaries for scientific accuracy.
Reviewed by Dr. Sarah Chen, PharmD y Dr. James Porter, PhD — Panda Peptides Research Team.
Last reviewed: April 2026.
This content summarizes published laboratory literature for research-reference purposes only. Products referenced by Panda Peptides are sold strictly for laboratory research use. This page is not intended as dosing, administration, treatment, or other human-use guidance.
